-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180134702A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180134702A1
公开(公告)日：2018-05-17
申请号：US15858240
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D471/04 , C07D519/00 , A61P35/04 , A61P1/12
CPC classification number: A61K31/496 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D471/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号：US09259470B2
公开(公告)日：2016-02-16
申请号：US14181418
申请日：2014-02-14
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou
IPC: A61K45/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D409/14 , C07D417/14 , C07D471/04 , A61K31/506 , C07F9/6558 , C07D403/04 , A61K31/513 , A61K31/53 , A61K31/444
CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586
Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 提供式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐，其可用于治疗过度增生，疼痛和炎性疾病。 公开了使用式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
公开(公告)号：US11964988B2
公开(公告)日：2024-04-23
申请号：US17274990
申请日：2019-09-06
Applicant: ARRAY BIOPHARMA INC.
Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Dean Kahn , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren , Shane M. Walls , Hailong Zhang
IPC: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22
CPC classification number: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22
Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2023/05/16/US11648243B2/abs.jpg.150x150.jpg)
公开(公告)号：US11648243B2
公开(公告)日：2023-05-16
申请号：US17108528
申请日：2020-12-01
Applicant: Array Biopharma Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. Mcfaddin , Megan L. Mckenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I:
or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.-
![Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors](/abs-image/US/2023/03/14/US11603374B2/abs.jpg.150x150.jpg)
公开(公告)号：US11603374B2
公开(公告)日：2023-03-14
申请号：US16962345
申请日：2019-01-18
Applicant: Array BioPharma Inc.
Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren
IPC: C07D487/04
Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
Patent Agency Ranking
![Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors](/abs-image/US/2022/12/13/US11524963B2/abs.jpg.150x150.jpg)
公开(公告)号：US11524963B2
公开(公告)日：2022-12-13
申请号：US16961973
申请日：2019-01-18
Applicant: Array Biopharma Inc.
Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Li Ren
IPC: A61K31/519 , C07D487/04
Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors](/abs-image/US/2021/03/23/US10953005B1/abs.jpg.150x150.jpg)
公开(公告)号：US10953005B1
公开(公告)日：2021-03-23
申请号：US16739846
申请日：2020-01-10
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61K31/551 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/10/15/US10441581B2/abs.jpg.150x150.jpg)
公开(公告)号：US10441581B2
公开(公告)日：2019-10-15
申请号：US15860894
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61K31/4545 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE](/abs-image/US/2019/04/11/US20190106438A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190106438A1
公开(公告)日：2019-04-11
申请号：US16156955
申请日：2018-10-10
Applicant: Loxo Oncology, Inc. , Array BioPharma Inc.
Inventor： Charles Todd Eary , Stacey Spencer , Zack Crane , Katelyn Chando , Sylvie Asselin , Weidong Liu , Mike Welch , Adam Cook , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Tony P. Tang
IPC: C07D519/00
Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133213A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133213A1
公开(公告)日：2018-05-17
申请号：US15860808
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/496 , A61P35/00 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/4995 , A61P35/02 , A61K45/06 , A61K31/444
CPC classification number: A61K31/496 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D471/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
44
records
(took 0.052 seconds)
